Image source: Adobe Stock/SciePro

News • Research presented at ESC 2022

Autoimmune disorders increase risk of cardiovascular disease

In a large epidemiological study researchers from KU Leuven show that patients with an autoimmune disorder have a substantially higher risk of developing cardiovascular disease than individuals without autoimmune disease.

The research, which was now published in The Lancet, shows for the first time that cardiovascular risks affect autoimmune disorders as a group of diseases with implications across a broad range of cardiovascular outcomes. The excess risk is particularly high among younger patients and suggests that autoimmune disorders are particularly important in causing premature cardiovascular disease, with the potential to result in a disproportionate loss of life years and disability.

Around ten percent of the population in high income regions like Europe and the United States has been diagnosed with one or multiple autoimmune disorders. Examples are rheumatoid arthritis, psoriasis, systemic sclerosis, lupus erythematosus and type I diabetes. Although earlier research has suggested associations between some of these disorders and a higher risk of cardiovascular disease, these studies were often too small and limited to selected autoimmune or selected cardiovascular conditions to draw conclusive evidence on the necessity of cardiovascular disease prevention among patients with autoimmune disease. 

Until now. At the annual congress of the European Society of Cardiology, held this weekend in Barcelona, an international research team led by KU Leuven presented the outcome of a thorough epidemiological investigation into possible links between nineteen of the most common autoimmune disorders and cardiovascular disease. The results of the study show that patients with autoimmune disease have a substantially higher risk (between 1.4 and 3.6 times depending on which autoimmune condition) of developing cardiovascular disease than people without an autoimmune disorder. This excess risk is comparable to that of type 2 diabetes, a well-known risk factor for cardiovascular disease. The research shows for the first time that cardiovascular risks affect autoimmune disease as a group of disorders, rather than selected disorders individually.

portrait of natalie conrad
Nathalie Conrad

Image source: KU Leuven

The results show that action is needed, says Nathalie Conrad, lead author of the study. "We see that the excess risk is comparable to that of type 2 diabetes. But although we have specific measures targeted at diabetes patients to lower their risk of developing cardiovascular disease (in terms of prevention and follow-up), we don’t have any similar measures for patients with autoimmune disorders." Conrad mentions the European Society of Cardiology guidelines on the prevention of cardiovascular diseases, which don’t yet mention autoimmunity as a cardiovascular risk factor (the guidelines only mention some specific disorders, like lupus) nor do they list any specific prevention measures for patients with autoimmune disease. 

Conrad hopes the study will raise awareness among patients with autoimmune disease and clinicians involved in the care of these patients, which will include many different specialties such as cardiologists, rheumatologists, or general practitioners. "We need to develop targeted prevention measures for these patients. And we need to do further research that helps us understand why patients with an autoimmune disorder develop more cardiovascular diseases than others, and how we can prevent this from happening."

This population-based study suggests that a much broader range of autoimmune disorders than previously recognized are associated with a variety of different cardiovascular problems

John McMurray

Speaking of the pathophysiology, the underlying mechanisms are still poorly understood. Conrad: "The general hypothesis is that chronic and systemic inflammation, which is a common denominator in autoimmune disorders, can trigger all sorts of cardiovascular disease. Effects of autoimmune disease on connective tissues, small vessels, and cardiomyocytes, and possibly some of the treatments commonly used to treat autoimmunity are also likely to contribute to patients’ cardiovascular risk. This really needs to be investigated thoroughly." 

Conrad, who owns an engineering degree and a PhD in medical sciences (epidemiology), performed the study during a two-year Marie Curie postdoctoral fellowship at KU Leuven. She worked closely together with Professor Geert Verbeke (KU Leuven), Professor Geert Molenberghs (KU Leuven and Hasselt University) and Professor Jan Verbakel (KU Leuven), who assisted in the bio-statistical and the clinical side of the study. Also part of the team was John McMurray (University of Glasgow, UK), a world-renowned cardiologist. He praises the very broad scope of the research. "This population-based study suggests that a much broader range of autoimmune disorders than previously recognized are associated with a variety of different cardiovascular problems." The cardiologist further mentions a possible solution in the short term. "Some of these problems are potentially preventable using readily available treatments such as statins." 


Source: KU Leuven

30.08.2022

Read all latest stories

Related articles

Photo

News • Study shows elevated risk

Finding connections between diabetes and heart valve disease

Individuals with diabetes display a substantially increased risk of disease in left-sided heart valves compared to controls without diabetes, a new comprehensive register study shows.

Photo

Article • Cardiology congress

ESC 2018: At the heart of research

When delegates from around 150 countries converge on Munich for ESC Congress 2018 they will no doubt reflect on what they themselves eat. Yes, nutrition is up for debate, questioning, for example,…

Photo

News • Improved detection and treatment

New trial shows benefits of smartphone-based atrial fibrillation screening

Atrial fibrillation screening using conventional smartphones more than doubles the detection and treatment rate in older people compared to routine screening, new research finds.

Related products

Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
Ziehm – Vision R

Surgical II-C-Arms

Ziehm – Vision R

Ziehm Imaging GmbH
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Subscribe to Newsletter